{"filing":{"accession_number":"0001297184-26-000045","cik":"0001297184","ticker":"AMPH","company_name":"Amphastar Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"amph-20260806x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806x8k.htm"},"events":[{"id":24583,"run_id":22291,"accession_number":"0001297184-26-000045","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release disclosing Amphastar's financial results for the three months ended June 30, 2026. The Item 2.02 disclosure explicitly states that \"Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly financial statements, revenue breakdowns by product, and operating metrics—all hallmarks of a standard earnings announcement. Material to investors as it provides quarterly financial performance data.","company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25189,"accession_number":"0001297184-26-000045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Amphastar's financial results for the three months ended June 30, 2026. The Item 2.02 disclosure explicitly states that \"Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly financial statements, revenue breakdowns by product, and operating metrics—all hallmarks of a standard earnings announcement. Material to investors as it provides quarterly financial performance data.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:16:42.797113+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25189,"accession_number":"0001297184-26-000045","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Amphastar's financial results for the three months ended June 30, 2026. The Item 2.02 disclosure explicitly states that \"Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly financial statements, revenue breakdowns by product, and operating metrics—all hallmarks of a standard earnings announcement. Material to investors as it provides quarterly financial performance data.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:16:42.797113+00:00","company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","filing_date":"2026-08-06"}]}